logo

PFE

Pfizer·NYSE
--
--(--)
--
--(--)
3.15 / 10
Netural

Pfizer's fundamental assessment is neutral, with a composite score of 3.15/10. Key positives include a low PB of 0.6923 (Group 2) and strong PCF at 22.74 (Group 4), indicating value on book and robust cash-flow multiples. However, sub-par GMAR (0.7495, Group 2) and CFOA (0.0305, Group 4) suggest operational inefficiencies. Overall, the fundamentals lean cautious yet not alarming, warranting watchful monitoring.

Fundamental(3.15)SentimentTechnical

Analysis Checks(6/10)

PB
Value0.69
Score1/3
Weight9.87%
1M Return8.87%
PCF
Value22.74
Score3/3
Weight16.35%
1M Return12.38%
EV/EBIT
Value15.77
Score2/3
Weight12.83%
1M Return10.47%
GPM
Value0.75
Score2/3
Weight10.51%
1M Return8.64%
GMAR
Value0.75
Score0/3
Weight5.85%
1M Return5.46%
PB-ROE
Value-0.34
Score1/3
Weight8.64%
1M Return7.86%
Income tax / Total profit (%)
Value-2.88
Score1/3
Weight0.32%
1M Return0.37%
CFOA
Value0.03
Score2/3
Weight12.30%
1M Return9.34%
GPOA
Value0.16
Score2/3
Weight9.99%
1M Return8.70%
NPM
Value0.21
Score2/3
Weight13.33%
1M Return10.41%
Is PFE fundamentally strong?
  • PFE scores 3.15/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 12.48% net margin, 19.92 P/E ratio, 1.66 P/B ratio, and -3.52% earnings growth, these metrics solidify its Netural investment rating.